Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
about
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis COral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
P2860
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@en
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@nl
type
label
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@en
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@nl
prefLabel
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@en
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@nl
P2860
P1476
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
@en
P2093
Elana S Rosenthal
Michael A Polis
P2860
P304
P356
10.1517/14656566.2016.1157580
P407
P577
2016-02-21T00:00:00Z